ReviewBMC pharmacology & toxicology2019
Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities.
Review in BMC pharmacology & toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Marine Antimicrobial Peptides: From Ocean Biodiversity to Genome Mining, Multi-Omics Discovery, and Biotechnological Innovation in the Battle Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- Rational engineering and yeast surface display of Epinecidin-1 peptides reveal antimicrobial activity and selective anticancer effects.Molecular biology reports · 2026Article
- Marine-derived Bioactive Compounds: A Promising Frontier against Multidrug-resistant Microbial Infections.Mini reviews in medicinal chemistry · 2026Review
- Marine bioactive peptides as potential therapeutic agents for wound healing - a review.Annals of medicine · 2025Review
- Marine Antimicrobial Peptides: Advances in Discovery, Multifunctional Mechanisms, and Therapeutic Translation Challenges.Marine drugs · 2025Review
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Compounds of Marine Origin with Possible Applications as Healing Agents.Marine drugs · 2024Review
- Antimicrobial Peptides: A Promising Solution to the Rising Threat of Antibiotic Resistance.Pharmaceutics · 2024Review
- Marine Antimicrobial Peptide Epinecidin-1 Inhibits Proliferation Induced by Lipoteichoic acid and Causes cell Death in non-small cell lung cancer Cells via Mitochondria Damage.Probiotics and antimicrobial proteins · 2024Article
- Review
- Exploration of the Antibacterial and Anti-Inflammatory Activity of a Novel Antimicrobial Peptide Brevinin-1BW.Molecules (Basel, Switzerland) · 2024Article
- Bioactive Peptides from Marine Organisms.Protein and peptide letters · 2024Review
- Epinecidin-1 (an active marine antimicrobial peptide): Effects on the survival of inoculatedFood science & nutrition · 2023Article
- Biological Function of Antimicrobial Peptides on Suppressing Pathogens and Improving Host Immunity.Antibiotics (Basel, Switzerland) · 2023Review
- A fucoidan plant drink reducesTranslational gastroenterology and hepatology · 2023Article
- Fish Epidermal Mucus as a Source of Diverse Therapeutical Compounds.International journal of peptide research and therapeutics · 2023Review
- Antimicrobial peptides as drugs with double response againstFrontiers in microbiology · 2023Review
- Antimicrobial Mechanisms and Clinical Application Prospects of Antimicrobial Peptides.Molecules (Basel, Switzerland) · 2022Review
- Antimicrobial Peptides Epinecidin-1 and Beta-Defesin-3 Are Effective against a Broad Spectrum of Antibiotic-Resistant Bacterial Isolates and Increase Survival Rate in Experimental Sepsis.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic-resistant pathogens are an emerging threat in this century. Epinecidin-1 is a multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides) has been shown to have extensive potentials as an alternative for current antibiotics. Due to the huge costs for the study and the production of a new drug, if an antimicrobial peptide has other beneficial functions in addition to antimicrobial activities, it would be preferred.
methodsIn this study, properties and applications of Epinecidin-1 were investigated and addressed comprehensively. To achieve this, the Google Scholar search engine and three databases of PubMed, Scopus, and Web of Science were used.
resultsEpinecidin-1 is a cationic AMP with an alpha-helical structure. Seven functional usages of this peptide have been reported in the literature including antibacterial, antifungal, antiviral, antiprotozoal, anticancer, immunomodulatory, and wound healing properties. Moreover, this peptide has high potential to be used as an active ingredient in cleaning solutions as well as application in vaccine production.
conclusionDue to significant antimicrobial activities tested on bacteria such as Staphylococcus aureus and Helicobacter pylori and also wound healing properties, Epi-1 has high potential to be considered as an important candidate for the production of new drugs and treatment of various infections including diabetic foot ulcer and peptic ulcer. Moreover, adjuvant-like properties of Epi-1 make it a suitable candidate for the studies related to an adjuvant. Other attractive properties such as anticancer effects have also been reported for this peptide which encourages further studies on this peptide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.